PT1003525E - Composicao e metodo para a regulacao da proliferacao e da morte celular - Google Patents

Composicao e metodo para a regulacao da proliferacao e da morte celular

Info

Publication number
PT1003525E
PT1003525E PT98938555T PT98938555T PT1003525E PT 1003525 E PT1003525 E PT 1003525E PT 98938555 T PT98938555 T PT 98938555T PT 98938555 T PT98938555 T PT 98938555T PT 1003525 E PT1003525 E PT 1003525E
Authority
PT
Portugal
Prior art keywords
composition
proliferation
regulation
cell death
dna
Prior art date
Application number
PT98938555T
Other languages
English (en)
Portuguese (pt)
Inventor
Nigel C Phillips
Mario C Fillion
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Publication of PT1003525E publication Critical patent/PT1003525E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT98938555T 1997-08-05 1998-08-05 Composicao e metodo para a regulacao da proliferacao e da morte celular PT1003525E (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5477797P 1997-08-05 1997-08-05
US7506798P 1998-02-18 1998-02-18
US7511198P 1998-02-18 1998-02-18
US8631798P 1998-05-21 1998-05-21

Publications (1)

Publication Number Publication Date
PT1003525E true PT1003525E (pt) 2003-03-31

Family

ID=27489673

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98938555T PT1003525E (pt) 1997-08-05 1998-08-05 Composicao e metodo para a regulacao da proliferacao e da morte celular

Country Status (17)

Country Link
US (2) US6329347B1 (enExample)
EP (1) EP1003525B1 (enExample)
JP (2) JP4335435B2 (enExample)
KR (1) KR100533576B1 (enExample)
AT (1) ATE227996T1 (enExample)
AU (1) AU736450B2 (enExample)
BR (1) BR9815602A (enExample)
CA (1) CA2299548C (enExample)
DE (1) DE69809561T2 (enExample)
DK (1) DK1003525T3 (enExample)
ES (1) ES2187047T3 (enExample)
HU (1) HU227921B1 (enExample)
IL (3) IL134371A0 (enExample)
NO (1) NO322450B1 (enExample)
NZ (1) NZ502674A (enExample)
PT (1) PT1003525E (enExample)
WO (1) WO1999007383A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100533576B1 (ko) 1997-08-05 2005-12-05 바이오니취 라이프 사이언시즈 인코포레이티드 세포증식 및 세포사멸 조절용 조성물 및 방법
NZ506406A (en) * 1998-02-18 2002-11-26 Bioniche Life Sciences Inc Compositions comprising Mycobacterium phlei DNA and methods for its use in the treatment of bladder cancer
WO2000033875A1 (en) * 1998-12-04 2000-06-15 Bioniche Life Sciences Inc. Chemotherapeutic composition and method
DK1135164T3 (da) * 1998-12-04 2004-12-20 Bioniche Life Sciences Inc Sammensætning til behandling af inflammation
US6809081B1 (en) * 1998-12-04 2004-10-26 Bioniche Life Sciences, Inc. Chemotherapeutic composition and method
WO2000059518A2 (en) * 1999-04-01 2000-10-12 Bioniche Life Sciences Inc. Composition and method for inducing apoptosis in prostate cancer cells
US6794368B1 (en) 1999-04-01 2004-09-21 Bioniche Life Sciences Inc. Composition and method for inducing apoptosis in prostate cancer cells
PT1181304E (pt) 1999-04-08 2008-01-23 Antisoma Res Ltd Actividade antiproliferativa de oligonucleótidos ricos em g e método de utilização dos mesmos para ligação a nucleolina
WO2001022979A1 (en) * 1999-09-29 2001-04-05 Bioniche Life Sciences Inc. Method to disrupt mitochondrial function
DE60036019T2 (de) * 1999-12-13 2008-05-29 Bioniche Life Sciences Inc., Belleville Synthetische oligonukleotide die therapeutisch nützlich sind
US7125858B2 (en) * 1999-12-28 2006-10-24 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
US20030044352A1 (en) * 2001-04-24 2003-03-06 Phillips Nigel C. Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls
US6673566B1 (en) 2002-01-10 2004-01-06 The United States Of America As Represented By The Secretary Of Agriculture Diagnosis of pathogen infections through analysis of nitrite production by antigen stimulated leukocytes
CN103169984B (zh) * 2006-07-25 2016-08-03 利普生技术有限公司 N末端聚唾液酸化
WO2012049654A1 (en) * 2010-10-13 2012-04-19 Bioniche Life Sciences, Inc. Bacterial ribonucleic acid cell wall compositions and methods of making and using them

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172815A (en) 1962-04-24 1965-03-09 Warner Lambert Pharmaceutical Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof
US4152423A (en) 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
FR2160326B1 (enExample) 1971-11-19 1975-02-07 Anvar
CA1020460A (en) 1973-02-23 1977-11-08 Wellcome Foundation Limited (The) Isolation of immunostimulating glycopeptide from bacteria
US3976544A (en) 1973-06-19 1976-08-24 The Agence Nationale De Valorisation De Le Recherche Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
FR2374042A1 (fr) 1976-06-04 1978-07-13 Merieux Inst Nouveau medicament immunostimulant et son procede de preparation
JPS54140710A (en) 1978-03-10 1979-11-01 Mitsui Toatsu Chem Inc Anti-tumor substance and its preparation
DE3011461C2 (de) 1980-03-25 1986-10-30 Dr. Madaus & Co, 5000 Köln Verwendung von Propionibakterien
US4520019A (en) 1982-04-29 1985-05-28 Ribi Immunochem Research, Inc. Stable composition and preparation thereof
US4579941A (en) 1982-08-13 1986-04-01 Mitsuitoatsu Chemicals, Inc. Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent
US4663306A (en) 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
GB8404280D0 (en) 1984-02-17 1984-03-21 Stanford J L Biological preparations
US4744984A (en) 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
AU691797B2 (en) 1993-01-29 1998-05-28 Vetrepharm, Inc. Immunotherapeutic composition
KR100533576B1 (ko) 1997-08-05 2005-12-05 바이오니취 라이프 사이언시즈 인코포레이티드 세포증식 및 세포사멸 조절용 조성물 및 방법

Also Published As

Publication number Publication date
NO20000576D0 (no) 2000-02-04
AU8723698A (en) 1999-03-01
BR9815602A (pt) 2001-12-11
IL134371A0 (en) 2001-04-30
JP4335435B2 (ja) 2009-09-30
DE69809561D1 (de) 2003-01-02
IL134371A (en) 2007-07-24
JP2001513504A (ja) 2001-09-04
IL180924A (en) 2010-11-30
IL180924A0 (en) 2007-07-04
EP1003525A1 (en) 2000-05-31
HUP0003012A3 (en) 2004-03-29
EP1003525B1 (en) 2002-11-20
DE69809561T2 (de) 2003-09-25
AU736450B2 (en) 2001-07-26
JP2008208140A (ja) 2008-09-11
HUP0003012A2 (hu) 2000-12-28
HU227921B1 (hu) 2012-06-28
WO1999007383A1 (en) 1999-02-18
CA2299548C (en) 2009-12-29
US6326357B1 (en) 2001-12-04
KR20010022643A (ko) 2001-03-26
NO20000576L (no) 2000-04-04
ES2187047T3 (es) 2003-05-16
KR100533576B1 (ko) 2005-12-05
WO1999007383B1 (en) 1999-03-25
NO322450B1 (no) 2006-10-09
US6329347B1 (en) 2001-12-11
DK1003525T3 (da) 2003-03-24
NZ502674A (en) 2002-06-28
CA2299548A1 (en) 1999-02-18
ATE227996T1 (de) 2002-12-15

Similar Documents

Publication Publication Date Title
IL180924A (en) Method for regulating cell proliferation and cell death
AU1926899A (en) Exploiting genomics in the search for new drugs
BR9710348A (pt) Métodos para testar a eficácia precisa de agentes ativos incluindo agentes quimioterapêuticos.
DE60031997D1 (de) Umkehrtransfektionsverfahren
DK1681355T3 (da) Sekvensspecifik DNA-rekombination i eukaryote celler
EE03955B1 (et) Nukleiinhappe kasutamine ravimi valmistamiseks imetaja reproduktiivtrakti vähemalt mõne raku transfekteerimiseks
ATE268904T1 (de) Zellbasiertes festphasentest
DE69012601D1 (de) Gentherapie durch stützgewebebezügliche Zellen.
FR2662698B1 (enExample)
ATE75778T1 (de) Immunosuppressionsfaktor.
TR200001486T2 (tr) Hiperkeratozlu deri hastalıklarının tedavisi için diol ve alfa-hidroksi asitten oluşan bir karışımın kullanılması
ATE226087T1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
BR9808529B1 (pt) oligopeptìdeo.
NO872420D0 (no) Elektrokjemisk cellesammensetning.
IT7922818A0 (it) Procedimento per mantenere attiva la cultura di fermenti.
DK323088A (da) Koeleanlaeg til braendeselsceller
NZ506406A (en) Compositions comprising Mycobacterium phlei DNA and methods for its use in the treatment of bladder cancer
HUP0102413A1 (hu) Vektorok nukleinsavak bevitelére, ezeket tartalmazó készítmények és alkalmazásuk
ES2145051T3 (es) Procedimiento para el cultivo de un tipo de celula en el procedimiento de cocultivo con celulas de higado.
ES2132027A1 (es) Desarrollo de una piel artificial mediante cultivo de queratinocitos sobre una base de fibrina y fibroblastos humanos y metodo de preparacion de esta piel para trasplante.
ES2180586T3 (es) Procedimiento para la determinacion de un analito.
ATE273027T1 (de) Zusammensetzung zur behandlung von entzündungen
RU96120030A (ru) Противолучевое средство
BG103733A (en) Isolated genes and proteins encoding resistance to photosensibilizers
ITUD950066A0 (it) Procedimento per la preparazione e la conservazione di colture cellulari, o di parti di cellule, allo stato pronto per dosaggi biologici